KCa channel targeting impairs DNA repair and invasiveness of patient‐derived glioblastoma stem cells in culture and orthotopic mouse xenografts which only in part is predictable by KCa expression levels

Prognosis of glioblastoma patients is still poor despite multimodal therapy. The highly brain‐infiltrating growth in concert with a pronounced therapy resistance particularly of mesenchymal glioblastoma stem‐like cells (GSCs) has been proposed to contribute to therapy failure. Recently, we have shown that a mesenchymal‐to‐proneural mRNA signature of patient derived GSC‐enriched (pGSC) cultures associates with in vitro radioresistance and gel invasion. Importantly, this pGSC mRNA signature is prognostic for patients' tumor recurrence pattern and overall survival. Two mesenchymal markers of the mRNA signature encode for IKCa and BKCa Ca2+‐activated K+ channels. Therefore, we analyzed here the effect of IKCa‐ and BKCa‐targeting concomitant to (fractionated) irradiation on radioresistance and glioblastoma spreading in pGSC cultures and in pGSC‐derived orthotopic xenograft glioma mouse models. To this end, in vitro gel invasion, clonogenic survival, in vitro and in vivo residual DNA double strand breaks (DSBs), tumor growth, and brain invasion were assessed in the dependence on tumor irradiation and K+ channel targeting. As a result, the IKCa‐ and BKCa‐blocker TRAM‐34 and paxilline, respectively, increased number of residual DSBs and (numerically) decreased clonogenic survival in some but not in all IKCa‐ and BKCa‐expressing pGSC cultures, respectively. In addition, BKCa‐ but not IKCa‐blockade slowed‐down gel invasion in vitro. Moreover, systemic administration of TRAM‐34 or paxilline concomitant to fractionated tumor irradiation increased in the xenograft model(s) residual number of DSBs and attenuated glioblastoma brain invasion and (numerically) tumor growth. We conclude, that KCa‐blockade concomitant to fractionated radiotherapy might be a promising new strategy in glioblastoma therapy. What's new? Some calcium‐activated potassium channels have been described as oncochannels involved in tumor progression and treatment resistance in a range of tumors, including glioblastoma. Here, the authors analyzed the radiosensitizing and anti‐invasive effects of targeting IKCa or BKCa channels in various patient‐derived glioblastoma stem cell cultures and orthotopic xenograft glioma mouse models. Pharmacological IKCa‐ and BKCa‐targeting radiosensitized and immobilized glioblastoma tumor cells in vitro and in vivo in some but not all IKCa‐ and BKCa‐expressing models. Due to the druggability of the two channels, their targeting might offer a novel approach in the treatmen